Acelyrin crew behind first thyroid eye disease medicine builds its potential competitor, with early data to boast
20 Mar 2024
Drug ApprovalImmunotherapy
Immunology biotech Acelyrin announced Wednesday morning that its experimental thyroid eye disease treatment improved symptoms in a small handful of patients as part of an early-stage clinical trial.
The drug, though in early development, could one day compete with Tepezza, which in 2020 became the first medicine approved to treat the autoimmune eye disease and has grown into a billion dollar-plus medicine. But unlike Tepezza, which is given as an infusion, Acelyrin’s experimental antibody lonigutamab comes as an injection and could make getting treatment easier for patients.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.